[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637534":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":31,"centralContacts":40,"locations":31,"responsibleParty":46,"collaborators":31,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":52,"sex":58,"minAge":59,"maxAge":31,"enrollmentInfo":60,"targetDuration":31,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":71,"whyStopped":31,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":31},{"fullName":5,"class":6},"Instituto Cardiovascular de Buenos Aires","OTHER",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Intravenous Furosemide","ACTIVE_COMPARATOR","Participants receive outpatient intravenous furosemide according to the study protocol during a structured ambulatory treatment session.",[13],"Drug: Intravenous furosemide bolus injections",{"label":15,"type":16,"description":17,"interventionNames":18},"Intravenous Furosemide + Acetazolamide","EXPERIMENTAL","Participants receive outpatient intravenous furosemide combined with oral acetazolamide during a structured ambulatory treatment session",[13,19],"Drug: ACETAZOLAMIDE oral capsule",{"label":21,"type":16,"description":22,"interventionNames":23},"Intravenous Furosemide + Hydrochlorothiazide","Participants receive outpatient intravenous furosemide combined with oral hydrochlorothiazide during a structured ambulatory treatment session",[13,24],"Drug: Hydrochlorothiazide (HCT)",[26,32,36],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Intravenous furosemide bolus injections","Intravenous loop diuretic therapy administered during outpatient treatment sessions according to protocol-defined dosing categories.",[9,15,21],null,{"type":27,"name":33,"description":34,"armGroupLabels":35,"otherNames":31},"ACETAZOLAMIDE oral capsule","Oral acetazolamide administered prior to intravenous loop diuretic therapy during outpatient treatment sessions",[15],{"type":27,"name":37,"description":38,"armGroupLabels":39,"otherNames":31},"Hydrochlorothiazide (HCT)","Oral hydrochlorothiazide administered prior to intravenous loop diuretic therapy during outpatient treatment sessions.",[21],[41],{"name":42,"role":43,"phone":44,"phoneExt":31,"email":45},"Lucrecia Maria Burgos, MD","CONTACT","541147877500","lburgos@icba.com.ar",{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"SPONSOR_INVESTIGATOR","Lucrecia Maria Burgos","MD","100637534","phase-4-tactic-hf-sequential-diuretic-strategies-in-ambulatory-worsening-heart-failure-100637534",false,"NCT07593612","TACTIC-HF: Sequential Diuretic Strategies in Ambulatory Worsening Heart Failure","TACTIC-HF: Thiazide or Acetazolamide Combination Versus Intravenous Furosemide in Ambulatory Worsening Heart Failure - a Randomized Crossover Trial","TACTIC-HF","Inclusion Criteria:\n\n* Age ≥18 years Chronic heart failure diagnosis according to current guideline definitions Ambulatory worsening heart failure requiring intravenous diuretic therapy in a specialized outpatient setting Evidence of clinical or objective congestion Chronic outpatient loop diuretic therapy Ability to comply with study procedures Written informed consent\n\nExclusion Criteria:\n\n* Hemodynamic instability or cardiogenic shock Requirement for immediate hospitalization Acute coronary syndrome, active infection, pulmonary embolism, or uncontrolled arrhythmia Severe electrolyte abnormalities Advanced renal failure requiring dialysis Pregnancy or breastfeeding Contraindication or allergy to study medications Current treatment with acetazolamide or thiazide diuretics Any condition that, in the opinion of the investigators, would make study participation unsafe or interfere with study procedures","ALL","18 Years",{"count":61,"type":62},60,"ESTIMATED","INTERVENTIONAL",[65],"PHASE4","TACTIC-HF is a prospective randomized crossover trial designed to compare three ambulatory diuretic strategies in patients with worsening heart failure treated in a specialized heart failure day-hospital program.\n\nParticipants will receive sequential treatment with:\n\n1. intravenous furosemide alone,\n2. intravenous furosemide combined with oral acetazolamide, and\n3. intravenous furosemide combined with oral hydrochlorothiazide.\n\nThe primary objective is to compare short-term natriuretic response between strategies. Secondary objectives include assessment of urine output, congestion parameters, and renal\u002Felectrolyte safety.\n\nEach participant will undergo repeated outpatient treatment sessions separated by washout periods, with standardized clinical and laboratory monitoring performed during each visit.\n\nThe study aims to evaluate pragmatic and clinically applicable ambulatory decongestion strategies using approved therapies commonly available in real-world practice.",[68],"Acute Heart Failure (AHF)",[70],"worsening heart failure","NOT_YET_RECRUITING","2026-05-11",{"date":74,"type":75},"2026-05-18","ACTUAL",{"date":77,"type":62},"2026-06-15",{"date":79,"type":62},"2027-01-15",{"name":48,"class":6}]